BVF PARTNERS L P/IL
CIK 1055947 · last filed 2025-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.70B
Companies
26
Total Filings
56
Lifetime Open-Market Net
$77.38M
Filer Profile
Reported Address
44 MONTGOMERY ST.40TH FLOOR
SAN FRANCISCO, CA 94104
Phone
(312) 506-6500
Related Filers
BVF INC/IL — 515 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND L P — 513 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND II LP — 509 joint filings, latest 2026-07-16
MARK N LAMPERT — 360 joint filings, latest 2026-07-16
BVF INVESTMENTS LLC — 264 joint filings, latest 2017-07-18
BVF Partners OS Ltd. — 237 joint filings, latest 2026-07-16
Biotechnology Value Trading Fund OS LP — 237 joint filings, latest 2026-07-16
BVF GP HOLDINGS LLC — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 353,412 | $114.96 | $40.63M | $139.55M | 1 | 2025-07-01 |
| PVLA | 282,223 | $150.13 | $42.37M | $0 | 1 | 2024-12-17 | |
| MLTX | Director | 9,005,700 | $12.51 | $112.66M | $0 | 1 | 2024-06-10 |
| ELDN | 10%+ Owner | 3,361,803 | $2.78 | $9.35M | $0 | 1 | 2024-05-13 |
| XOMA Royalty Corp (XOMAP) Delisted | Director | 1,556,696 | $24.98 | $38.89M | $0 | 1 | 2022-05-20 |
| RAIN | Director | 1,367,838 | $0.74 | $1.01M | $266.23M | 3 | 2022-01-10 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,578,732 | $90.00 | $142.09M | -$290.16M | 3 | 2021-10-08 |
| OLMA | Director | 535,638 | $10.22 | $5.47M | $0 | 1 | 2021-05-26 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,279,831 | $0.04 | $146.6K | $1.47M | 2 | 2021-02-19 |
| CTMX | 358,450 | $3.29 | $1.18M | $0 | 1 | 2021-02-18 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 2,194,410 | $40.17 | $88.15M | $1.20M | 1 | 2020-08-20 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 346,627 | $38.00 | $13.17M | $4.44M | 1 | 2019-10-25 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 2,734,725 | $9.09 | $24.86M | $8.53M | 2 | 2017-06-14 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 274,882 | — | — | $1.16M | 1 | 2017-06-07 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 3,298,293 | — | — | $5.57M | 2 | 2014-12-17 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 124,580 | — | — | $0 | 1 | 2014-03-25 | |
| PTN | 10%+ Owner | 17,525 | $11.80 | $206.8K | -$5.62M | 2 | 2014-03-03 |
| CCXI | 10%+ Owner | 2,079,532 | $12.32 | $25.62M | $10.51M | 3 | 2013-12-05 |
| LGND | 10%+ Owner | 4,506,145 | $284.47 | $1.28B | -$46.58M | 7 | 2013-01-25 |
| NBIX | 10%+ Owner | 6,658,212 | $156.22 | $1.04B | -$8.66M | 4 | 2012-02-10 |
| ICAGEN INC (ICGN) Delisted | 10%+ Owner | 219,700 | — | — | $4.56M | 1 | 2011-09-09 |
| CAPS | 10%+ Owner | 820 | $0.18 | $149 | $149.9K | 1 | 2011-06-29 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 18,772,784 | — | — | $8.96M | 1 | 2011-04-07 |
| RPRX | 10%+ Owner | 2,297,776 | $58.61 | $134.67M | -$4.03M | 1 | 2009-09-21 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 855,770 | $15.50 | $13.26M | -$20.11M | 1 | 2009-09-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,459,999 | — | — | $181.2K | 3 | 2008-12-05 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-17 | RAIN | Buy (P) | +580,000 | $8.27M | EDGAR |
| 2021-05-17 | RAIN | Buy (P) | +11,333,090 | $191.03M | EDGAR |
| 2021-02-19 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | — | — | $0 | EDGAR |
| 2021-02-18 | CTMX | — | — | $0 | EDGAR |
| 2020-08-20 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +61,630 | $1.20M | EDGAR |
| 2020-06-10 | Merus N.V. (MRUS) Delisted | Buy (P) | +872,540 | $13.26M | EDGAR |
| 2020-01-15 | Merus N.V. (MRUS) Delisted | Buy (P) | +587,734 | $8.80M | EDGAR |
| 2019-10-25 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +1,185,590 | $4.44M | EDGAR |
| 2018-12-17 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +1,225,000 | $1.47M | EDGAR |
| 2018-12-04 | — | Sell (S) | −6,314,000 | -$11.58M |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.